ClinicalTrials.gg
CompletedNCT01028391Updated May 12, 2017Results posted

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

A Phase 3 interventional study of Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d. and Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d. in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Sep 2007, registered Dec 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
52nd of 197
317 · median 102
Started
2007
with 16 others
Phase 3
74 of 198
none open now
Registered
77th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 52nd largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 77th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in patients with type 2 diabetes mellitus (T2DM) with inadequate glycemic control.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must complete the double-blind base study (MK-0431-064-00)(NCT00397631) and have at least 75% compliance with study medication during the base study treatment period.
  • Women of must continue to comply with the protocol-specified methods
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    Sitagliptin + Pioglitazone

    Drug: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d. · Drug: Metformin

  • Active comparator
    Pioglitazone + Placebo

    Drug: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d. · Drug: Metformin

Interventions

  • DrugSitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.

    Drug page: Sitagliptin

    Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.

  • DrugPioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.

    Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.

  • Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.

06

What researchers measure

Primary outcomes

  1. Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54

    HbA1c is measured as percent. Thus this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.

    Time frame: Baseline and 54 Weeks

Secondary outcomes

  1. Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54

    Change from baseline at Week 54 is defined as Week 54 minus Week 0.

    Time frame: Baseline and Week 54

07

Results

Posted Feb 10, 2010

Participant flow

First patient in the 30-week extension study: 21-Sep-2007. Last patient last visit of the 30-week extension study: 23-Jan-2009; 53 study centers worldwide.

Participant flow — Overall Study
MilestoneSitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.
Started164153
Completed150142
Not completed1411
Withdrew: Adverse event40
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up34
Withdrew: Physician decision01
Withdrew: Withdrawal by subject63
Withdrew: Needed excluded medication11

Outcome measures

PrimaryChange From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54

HbA1c is measured as percent. Thus this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.

Time frame:
Baseline and 54 Weeks
Reported as:
Least squares mean · Percent HbA1c
Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54
Percent HbA1cSitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.
Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54-2.37 (-2.54 to -2.19)-1.86 (-2.04 to -1.68)
Statistical analysis
  • Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. vs Pioglitazone 45 mg q.d. · Mean difference (net): -0.51 · 95% CI -0.76 to -0.26This is a difference in least squares means, based on an ANCOVA model with terms for treatment and baseline (i.e., Week 0 of the 24-week base study) HbA1c.
SecondaryChange From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54

Change from baseline at Week 54 is defined as Week 54 minus Week 0.

Time frame:
Baseline and Week 54
Reported as:
Least squares mean · mg/dL
Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54
mg/dLSitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.
Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54-61.3 (-66.7 to -55.9)-52.8 (-58.4 to -47.2)
Statistical analysis
  • Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. vs Pioglitazone 45 mg q.d. · Mean difference (net): -8.5 · 95% CI -16.3 to -0.7This is a difference in least squares means, based on an ANCOVA model with terms for treatment and baseline (i.e., Week 0 of the 24-week base study) FPG.

Adverse events

Collected over Weeks 24 to 54 (i.e., the entire 30-week extension study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.—5/164 (3%)8/164 (4.9%)
Pioglitazone 45 mg q.d.—3/153 (2%)8/153 (5.2%)
Most frequent serious events
Most frequent serious events
EventSitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.
All Infections and InfestationsInfections and infestations3/1642/153
AppendicitisInfections and infestations2/1640/153
Gastroenteritis viralInfections and infestations0/1641/153
Pyelonephritis chronicInfections and infestations0/1641/153
All Nervous System DisordersNervous system disorders1/1641/153
Cerebrovascular accidentNervous system disorders0/1641/153
All Cardiac DisordersCardiac disorders1/1640/153
Coronary artery insufficiencyCardiac disorders1/1640/153
Lobar pneumoniaInfections and infestations1/1640/153
PresyncopeNervous system disorders1/1640/153
Most frequent other events
Most frequent other events
EventSitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.
All Infections and InfestationsInfections and infestations8/1648/153
NasopharyngitisInfections and infestations8/1648/153

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.Total
Mean51.4 ± 10.052.3 ± 11.551.8 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.Total
Female7863141
Male8690176
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.Total
White9385178
Black7310
Asian424183
Other222446
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percent)Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d.Pioglitazone 45 mg q.d.Total
Mean9.4 ± 1.29.4 ± 1.29.4 ± 1.2
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011 Feb;65(2):154-64. doi: 10.1111/j.1742-1241.2010.02589.x. PubMed 21235696 ↗
  • Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17. PubMed 22405352 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in Jan 2009, 16 months.

Results were first posted in Feb 2010, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2009
First posted
Dec 9, 2009
StartActual
Sep 1, 2007
Primary completionActual
Jan 1, 2009
CompletionActual
Jan 1, 2009
Results first posted
Feb 10, 2010
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01028391
Responsible party
Sponsor
First posted
Dec 9, 2009
Start date
Sep 1, 2007
Primary completion
Jan 1, 2009
Completion
Jan 1, 2009
Results posted
Feb 10, 2010
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion